Claes Ekstrom
Investment Team & Managing Director - Head of Life Sciences @ Innovatus Capital Partners
New York, United States
Claes Ekstrom is a post-ipo debt investor at Innovatus Capital Partners in New York focused on Medical and Health Care. Ekstrom has over 20 years of experience in asset-backed investing, mergers & acquisitions and corporate finance across healthcare and various other industries. Prior to joining Innovatus Capital Partners, LLC in January of 2016, Mr. Ekstrom was a member of the Perella Weinberg Partners' Asset Based Value Strategy Investment Team, wherehe focused on corporate, healthcare, and consumer opportunities. From 2011 to 2013, Mr. Ekstrom was a full-time consultant to the Asset Based Value Strategy Investment Team and provided advice on a range of matters. From 2009 to 2011, Mr. Ekstrom was a Managing Director at Bentley Associates, a boutique investment bank focusing on middle market M&A and private placements. From 2007 to 2009, he served as a Director in the M&A group at Merrill Lynch & Co. From 2004 to 2007, he was a senior member of the healthcare investment banking group at Lehman Brothers, where he provided M&A and financing advice to leading healthcare companies and healthcare investors. Mr. Ekstrom started his investment banking career with Merrill Lynch & Co. in 1996 and was a member of the M&A group where he executed M&A transactions across a wide range of industries.Mr. Ekstrom received a M.Sc. in Economics and Business from the Stockholm School of Economics.
- Total investments:
- 10
- Last investment:
- Lead investor:
- 60%
Last updated:
For AI agents: llms.txt
Industries Claes Ekstrom invests in
Stages Claes Ekstrom invests in
Countries Claes Ekstrom invests in
Round sizes
Round size
- Post-IPO Debt
- $27M–$75M
Investment Focus
Industry
- Medical 4 (40%)
- Health Care 4 (40%)
- Biotechnology 4 (40%)
- Analytics 3 (30%)
- Bioinformatics 3 (30%)
Stage
- Post-IPO Debt 3 (30%)
- Angel 1 (10%)
- Series C 1 (10%)
- Series F 1 (10%)
- Series H 1 (10%)
Country
- United States 6 (60%)
- Sweden 1 (10%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Syapse
|
To achieve more precise care for every patient, we need to transform real-world evidence into insights that can directly impact care. At Syapse, that is real-world care. It’s found in the way we empower healthcare organizations to work together in active, transparent partnerships, delivering complete patient insights to answer the questions thatmatter and then purposefully applying it at where patients receive care – driving real impact for cancer patients and beyond. | $35M / Venture - Series Unknown / Jul 27, 2022 | |
Eiger BioPharmaceuticals
|
Eiger BioPharmaceuticals is a privately held biotechnology company that develops a novel antiviral therapy for Hepatitis Delta, a life-threatening, Orphan Disease with high unmet medical need and no approved therapy. The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Itsstrategy is predicated upon time and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients. | $5M / Post-IPO Equity / Jun 07, 2022 | |
|
Eiger BioPharmaceuticals
|
Eiger BioPharmaceuticals is a privately held biotechnology company that develops a novel antiviral therapy for Hepatitis Delta, a life-threatening, Orphan Disease with high unmet medical need and no approved therapy. The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Itsstrategy is predicated upon time and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients. | $75M / Post-IPO Debt / Jun 07, 2022 | |
DNAnexus
|
DNAnexus develops a cloud platform and global network designed for scientific collaboration and accelerated discovery. It provides security, scalability, and collaboration for enterprises and organizations that are pursuing genomic-based approaches to health in order to accelerate medical discovery. DNAnexus is supporting customers around the worldthat are tackling some of the most challenging and exciting opportunities in human health.The company was founded in 2009 and is based in Mountain View, California. | $200M / Series H / Mar 08, 2022 | |
Exagen
|
Exagen is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. Exagen has developed and is commercializing a portfolio of innovative testing products under its AVISE brand, several of which are based onour proprietary Cell-Bound Complement Activation Products, or CB-CAPs, technology. Exagen’s goal is to enable providers to improve care for patients through the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases, including rheumatoid arthritis and lupus.Exagen was established in 2002 and is headquartered in Vista, California. | $27.2M / Post-IPO Debt / Oct 25, 2021 | |
Personal Genome Diagnostics
|
Personal Genome Diagnostics develops a patient-specific analysis of the cancer genome by using advanced tools and technologies. They were the first to sequence and analyze whole human cancer exomes and subsequently identified many alterations responsible for the development of cancer. They have described the principles underlying the genetic basisof human cancer and have developed novel technologies for non-invasive “liquid biopsy” approaches in cancer.Through PGDx, our founders bring their proprietary methods and expertise to research teams worldwide. The services help oncologists and translational scientists sequence and analyze cancer genomes and identify mutations to characterize aspects of the disease. Their expertise in genome analysis ranges from sample preparation and sequencing to data interpretation and analysis. They specialize in high-throughput next-generation sequencing and proprietary algorithms to identify alterations in complex cancer genomes and have developed novel technologies for non-invasive “liquid biopsy” approaches in cancer.Personal Genome Diagnostics was founded in 2010 and is based in Baltimore, Maryland, United States. | $103M / Series C / Feb 10, 2021 | |
Arkion
|
Arkion provides accurate, scalable data, ensuring that your grid is robust and ready for the next century—and beyond. | $505K / Angel / Jan 13, 2020 | |
ConforMIS
|
Conformis is a medical technology company that uses its proprietary iFit® Image-to-Implant® technology platform to develop, manufacture, and sell joint replacement implants and instruments that are individually sized and shaped, which it refers to as personalized, individualized, or sometimes as customized, to fit each patient’s unique anatomy.Conformis offers a broad line of sterile, personalized knee and hip implants and single-use instruments delivered to hospitals and ambulatory surgical centers. | $30M / Post-IPO Debt / Jun 26, 2019 | |
|
DNAnexus
|
DNAnexus develops a cloud platform and global network designed for scientific collaboration and accelerated discovery. It provides security, scalability, and collaboration for enterprises and organizations that are pursuing genomic-based approaches to health in order to accelerate medical discovery. DNAnexus is supporting customers around the worldthat are tackling some of the most challenging and exciting opportunities in human health.The company was founded in 2009 and is based in Mountain View, California. | $68M / Series F / Feb 06, 2019 | |
|
Personal Genome Diagnostics
|
Personal Genome Diagnostics develops a patient-specific analysis of the cancer genome by using advanced tools and technologies. They were the first to sequence and analyze whole human cancer exomes and subsequently identified many alterations responsible for the development of cancer. They have described the principles underlying the genetic basisof human cancer and have developed novel technologies for non-invasive “liquid biopsy” approaches in cancer.Through PGDx, our founders bring their proprietary methods and expertise to research teams worldwide. The services help oncologists and translational scientists sequence and analyze cancer genomes and identify mutations to characterize aspects of the disease. Their expertise in genome analysis ranges from sample preparation and sequencing to data interpretation and analysis. They specialize in high-throughput next-generation sequencing and proprietary algorithms to identify alterations in complex cancer genomes and have developed novel technologies for non-invasive “liquid biopsy” approaches in cancer.Personal Genome Diagnostics was founded in 2010 and is based in Baltimore, Maryland, United States. | $42M / Oct 04, 2018 |
Co-Investors
About Innovatus Capital Partners
Innovatus Capital Partners, they focus on both real and financial assets. Their firm's investment in strategies that identifies distressed, disruptive, and growth opportunities.
Innovatus Capital Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Claes Ekstrom
Investment Team & Managing Director - Head of Life Sciences
|
|||
|
Andrew Dym
Founding Partner
|
|||
|
David Schiff
Founding Partner
|
|||
2 more contacts available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Claes Ekstrom invest in?
Claes Ekstrom invests primarily in Medical, Health Care and Biotechnology startups, most often at Post-IPO Debt and Angel stage. Most of the 10 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Claes Ekstrom's check size?
Claes Ekstrom typically joins rounds of $27M–$75M at Post-IPO Debt. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Claes Ekstrom participates in.
When did Claes Ekstrom last invest?
The most recent investment recorded for Claes Ekstrom closed in Jul 2022. Shizune tracks 10 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
